EVO200
Prevention of recurrent Bacterial Vaginosis (BV)
Phase 1Investigational (QIDP designated)
Key Facts
Indication
Prevention of recurrent Bacterial Vaginosis (BV)
Phase
Phase 1
Status
Investigational (QIDP designated)
Company
About Evofem Biosciences
Evofem Biosciences is dedicated to addressing critical unmet needs in women's healthcare through innovative, hormone-free products. The company successfully launched Phexxi®, a first-in-class vaginal pH modulator for on-demand contraception, and acquired Solosec®, a single-dose oral antibiotic for bacterial vaginosis. With a growing commercial footprint and a pipeline exploring new indications, Evofem is targeting a multi-billion dollar market opportunity in contraception and sexual health.
View full company profile